Noubar Afeyan Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00. Following the transaction, the director now directly owns 2,071,931 shares in the company, valued at approximately $221,945,248.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total transaction of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total transaction of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Stock Performance

Shares of Moderna stock opened at $105.14 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The firm has a market cap of $40.26 billion, a price-to-earnings ratio of -8.47 and a beta of 1.62. Moderna, Inc. has a one year low of $62.55 and a one year high of $163.24. The stock’s 50-day moving average is $99.86 and its 200-day moving average is $93.57.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter in the prior year, the firm posted $3.61 EPS. The business’s revenue was down 44.9% on a year-over-year basis. Equities analysts predict that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRNA has been the topic of a number of analyst reports. HSBC reissued a “reduce” rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Thursday. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $125.00 price target on shares of Moderna in a research report on Thursday, March 28th. Finally, Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and a consensus price target of $126.49.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. RB Capital Management LLC increased its position in shares of Moderna by 7.5% in the first quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock valued at $391,000 after acquiring an additional 158 shares during the last quarter. Synovus Financial Corp increased its position in shares of Moderna by 8.0% during the 1st quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock worth $704,000 after purchasing an additional 300 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Moderna by 5.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock worth $170,121,000 after purchasing an additional 47,755 shares in the last quarter. Blair William & Co. IL boosted its holdings in shares of Moderna by 12.4% in the 1st quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock valued at $2,689,000 after buying an additional 1,724 shares during the last quarter. Finally, Sei Investments Co. grew its stake in shares of Moderna by 41.4% in the first quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock valued at $10,019,000 after buying an additional 17,031 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.